Beneficial effects of cholesterol absorption inhibitor,ezetimibe on impaired endothelial function in patients with metabolic syndrome.

Trial Profile

Beneficial effects of cholesterol absorption inhibitor,ezetimibe on impaired endothelial function in patients with metabolic syndrome.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Ezetimibe (Primary)
  • Indications Hypercholesterolaemia; Metabolic syndrome
  • Focus Therapeutic Use
  • Acronyms EZET
  • Most Recent Events

    • 31 Jul 2017 Status changed from recruiting to discontinued.
    • 19 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top